Gene Therapy Clinical Candidate Development for Carbamoyl Phosphate Synthetase Deficiency

氨基甲酰磷酸合成酶缺乏症的基因治疗临床候选药物开发

基本信息

  • 批准号:
    10339836
  • 负责人:
  • 金额:
    $ 38.92万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-02-01 至 2024-01-31
  • 项目状态:
    已结题

项目摘要

Project Summary/Abstract The urea cycle is the major pathway for detoxification of ammonia in mammals. Carbamoyl phosphate synthetase 1 (CPS1) deficiency is a neurologically-devastating condition that, while late- onset does occur, the disorder primarily is a condition affecting neonates. The deficiency of this enzyme is characterized clinically by periodic episodes of hyperammonemia resulting in progressive irreversible neurological injury and severe CNS impairment, particularly during a period of critical postnatal development; the condition is associated with a high likelihood of early neonatal mortality. The long-term goal of this program is to develop a clinical candidate gene therapy vector that will result in ammonia control and restore ureagenesis in CPS1 deficiency. Recent advances in gene therapy have led to the concept of using adeno-associated virus (AAV)-based biotechnology to treat CPS1 deficiency; at present, this monogenic disorder has no completely effective therapy except liver transplantation, though often not occurring until the infant has reached a size where successful transplantation is more likely but multiple episodes of neurological injury have been sustained. In addition to being one of the most difficult urea cycle disorders to treat clinically, the development of a gene therapy approach has been hampered by several challenges. First, until recently, there were no animal models of the disorder. Second, CPS1, the most abundant mitochondrial protein in the human liver, must be expressed at high level in hepatocytes. And third, the size of the CPS1 cDNA at 4.5kb places limitations on the expression cassette size; this may be the greatest hindrance for a clinically translatable vector that can be produced at high titer. This proposal seeks to advance a gene therapy approach using small hepatocyte-specific gene regulatory elements to produce a compact CPS1-expressing AAV and a hybrid/dual vector AAV as approaches for this poorly treated disorder. The Lipshutz laboratory recently developed two murine models of CPS1 deficiency and has published and preliminary data on the efficacy of an AAV approach; this proposal is to complete the development and bring forth a clinical candidate vector. Preliminary and published data: The research group has: 1) developed a conditional Cps1-deficient knockout mouse, replicating neonatal onset CPS1 deficiency; 2) demonstrated hepatocyte-specific expression of CPS1 from single vector AAV that has led to plasma ammonia control; 3) developed a dual (or split) AAV approach to express CPS1 in the liver; and 4) has produced humanized mice where CPS1-deficient hepatocytes have repopulated the murine liver; the latter is essential for testing these vector approaches. Specific Aim 1: Optimize the AAV constructs for hepatic CPS1 expression and identify the optimal candidate to advance. Specific Aim 2: Test different hepatotropic serotypes of AAV vector- based CPS1 expression utilizing the optimized transgene cassette in a Cps1-deficient humanized mouse model. The proposed research is significant as it is expected that at completion a final clinical candidate and serotype will have been chosen for establishing hepatic gene replacement for CPS1 deficiency.
项目摘要/摘要尿素循环是哺乳动物体内氨解毒的主要途径。 氨基甲酰磷酸合成酶1(CPS1)缺乏症是一种神经学破坏性的疾病,虽然晚期- 发病确实会发生,这种疾病主要是影响新生儿的一种情况。这种酶的缺陷是 以导致进行性不可逆转的高氨血症周期性发作为临床特征 神经损伤和严重的中枢神经系统损伤,特别是在出生后发育的关键时期; 这种情况与早期新生儿死亡的可能性很高。这项计划的长期目标是 是开发一种临床候选基因治疗载体,将导致氨控制和恢复尿失禁 CPS1缺乏症。基因治疗的最新进展催生了使用腺相关病毒的概念 以AAV为基础的生物技术治疗CPS1缺乏症;目前,这种单基因疾病还没有完全 除肝移植外的有效治疗,尽管通常在婴儿达到一定大小后才会发生 如果移植成功的可能性更大,但已经遭受了多次神经损伤。 除了是临床上最难治疗的尿素循环障碍之一外,一种基因的发展 治疗方法一直受到几个挑战的阻碍。首先,直到最近,还没有动物模型 失调症的症状。其次,必须表达CPS1,这是人类肝脏中含量最丰富的线粒体蛋白 在肝细胞中处于高水平。第三,4.5kb的cps1的大小限制了表达 盒式磁带大小;这可能是临床上可翻译的载体能够在高密度下产生的最大障碍 效价。这项建议寻求利用小肝细胞特异性基因调控来推进基因治疗方法。 产生紧凑的表达CPS1的AAV和混合/双载体AAV的元件作为实现这一点的方法 治疗不当的精神障碍。利普舒茨实验室最近建立了两种CPS1缺乏症和 已经公布了关于AAV方法有效性的初步数据;这项提议是为了完成 开发并推出临床候选载体。初步和公布的数据:研究小组 有:1)建立了条件Cps1缺陷基因敲除小鼠,复制了新生儿发病的CPS1缺陷;2) 单载体AAV肝细胞特异性表达CPS1导致血氨 对照;3)开发了一种双重(或分离)AAV方法在肝脏中表达CPS1;以及4)已经产生了 人源化的小鼠,CPS1缺陷的肝细胞重新填充了小鼠的肝脏;后者对于 测试这些矢量方法。具体目标1:优化肝CPS1表达和表达的AAV构建 找出晋升的最佳人选。特定目标2:检测不同嗜肝型AAV载体- 利用优化的转基因盒在Cps1缺陷人源化小鼠模型中基于CPS1的表达。 这项拟议的研究意义重大,因为预计在完成时,最终的临床候选和血清型 将被选择用于建立针对CPS1缺乏症的肝脏基因替代。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gerald S Lipshutz其他文献

Gerald S Lipshutz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gerald S Lipshutz', 18)}}的其他基金

Gene Therapy Clinical Candidate Development for Carbamoyl Phosphate Synthetase Deficiency
氨基甲酰磷酸合成酶缺乏症的基因治疗临床候选药物开发
  • 批准号:
    10540348
  • 财政年份:
    2022
  • 资助金额:
    $ 38.92万
  • 项目类别:
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency
了解精氨酸酶缺乏的机制并预防独特的神经病理学
  • 批准号:
    10318637
  • 财政年份:
    2019
  • 资助金额:
    $ 38.92万
  • 项目类别:
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency
了解精氨酸酶缺乏的机制并预防独特的神经病理学
  • 批准号:
    9908195
  • 财政年份:
    2019
  • 资助金额:
    $ 38.92万
  • 项目类别:
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency
了解精氨酸酶缺乏的机制并预防独特的神经病理学
  • 批准号:
    10540721
  • 财政年份:
    2019
  • 资助金额:
    $ 38.92万
  • 项目类别:
Understanding the Mechanism and Preventing the Unique Neuropathology of Arginase Deficiency
了解精氨酸酶缺乏的机制并预防独特的神经病理学
  • 批准号:
    10080755
  • 财政年份:
    2019
  • 资助金额:
    $ 38.92万
  • 项目类别:
Cell and Gene Replacement Strategies for Arginase Deficiency
精氨酸酶缺乏症的细胞和基因替代策略
  • 批准号:
    9289701
  • 财政年份:
    2017
  • 资助金额:
    $ 38.92万
  • 项目类别:
Cell and Gene Replacement Strategies for Arginase Deficiency
精氨酸酶缺乏症的细胞和基因替代策略
  • 批准号:
    10115139
  • 财政年份:
    2017
  • 资助金额:
    $ 38.92万
  • 项目类别:
Development of Molecular Therapy for Carbamoyl Phosphate Synthetase Deficiency
氨基甲酰磷酸合成酶缺乏症分子治疗的进展
  • 批准号:
    8996735
  • 财政年份:
    2015
  • 资助金额:
    $ 38.92万
  • 项目类别:
Development of Molecular Therapy for Carbamoyl Phosphate Synthetase Deficiency
氨基甲酰磷酸合成酶缺乏症分子治疗的进展
  • 批准号:
    8872239
  • 财政年份:
    2015
  • 资助金额:
    $ 38.92万
  • 项目类别:
Immunologic Aspects of In Utero or Neonatal AAV-Based Gene Therapy
子宫内或新生儿基于 AAV 的基因治疗的免疫学方面
  • 批准号:
    8915936
  • 财政年份:
    2014
  • 资助金额:
    $ 38.92万
  • 项目类别:

相似海外基金

How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
  • 批准号:
    23K00129
  • 财政年份:
    2023
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
  • 批准号:
    2883985
  • 财政年份:
    2023
  • 资助金额:
    $ 38.92万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了